Recent Finacing
Recent Raise
Ardelyx is a Fremont biopharma developing oral therapeutics for mineral metabolism and metabolic disorders, including clinical-stage RDX5791 for IBS-C and sodium absorption prevention and preclinical CKD and T2D programs.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors